A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

NCT05347485 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cilta-cel
DRUG: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

Sponsor

Janssen Scientific Affairs, LLC